The monomeric compound alternol has been found to promote apoptosis and ROS-dependent ER stress via the PERK-ATF4-CHOP axis and the IRE1α–XBP1-CHOP axis in prostate cancer cells, PC-3, 22RV1, and C4-2, where the NF-κB inhibitor Imoxin and SN50 treatment were able to suppress alternol-mediated ER stress and apoptosis [35]. Here, NFKB1 is linked to prostate carcinoma.